BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

The reelection of former President Donald Trump, coupled with Republicans gaining the Senate majority and poised to gain the House majority, ...

The agency’s ability to hire and retain skilled employees may be in jeopardy given Trump ally Robert F. Kennedy Jr.’s ...

While A.I. promises breakthroughs, industry leaders warn that transparency and patient safety must remain front and center.

The new director at the FDA overseeing medical devices will confront criticisms about hasty approvals as she ushers in ...

The FDA is proposing the removal of phenylephrine, a popular nasal decongestant, in oral form from over-the-counter use. Here ...

The new Trump administration is likely to reduce subsidies for Affordable Care Act insurance plans and roll back Medicaid ...

It combines two focused and complementary businesses," DS Smith CEO Miles Roberts said in a news release at that time. On Oct. 11, International Paper shareholders approved the deal. The approval ...

Visa plans to lay off around 1,400 employees and contractors, focusing heavily on technology roles, by the end of 2024. Despite the cuts, Visa aims to continue its growth trajectory by evolving ...

A large crowd gathered at Dighalipukhuri in Assam's Guwahati today to protest against the state government's proposal to cut trees to construct a new flyover. The proposed flyover will connect ...

Orylnvah is a broad-spectrum oral penem antibiotic for women who have limited or no alternative treatment options, according to an Oct. 24 FDA news release. In trials, Orylnvah had a 62% composite ...

The US Food and Drug Administration (FDA) approved a new oral antibiotic to treat uncomplicated urinary tract infections (uUTIs). Orlynvah (sulopenem etzadroxil and probenecid) is a broad-spectrum ...